HEALTHLINES

Sponsored Research and the American Recovery and Reinvestment Act of 2009

The NIH and NSF have begun to announce several programs for delivering economic stimulus funds out to institutions. We will be emailing relevant opportunities to the research community as they are announced. At this point, infrastructure awards – funds for equipment (both shared and high-end cost), alterations and renovations, and construction – are priorities for funding. The second major (and largest) category of funding is for peer-reviewed science that would benefit from a two-year boost. NIH is specifically considering using administrative supplements to ongoing projects, Challenge Grants for new projects, competitive supplements adding new scope/aims to existing projects, and short-term grants among the 14,000 proposals that were deemed worthy of funding by study sections and advisory councils but had no funds available under the regular appropriation.

Dr. Raynard Kington, Interim Director of the NIH, held a conference call with members of the AAMC and stated that investigators will be approached by program officials for administrative supplements and the short-term grants. For these, NIH will be comparing specific aims and the programmatic interests of the institute as well as the ability of the project to show significant advances in the science in a two-year time period. They will not be “calling down the list” in order of priority score. Program announcements and requests for applications will drive the infrastructure, competitive supplements, and Challenge Grants.

What do you need to know?

• Be ready to move quickly – Both program announcements and direct approaches from NIH will have short turn around times. The research administration structure at UM will be very supportive getting things out the door!

• Be ready to rethink your costs and discuss them – We are anticipating that if a four- or five-year program is negotiated down to two years, the scientific scope, and therefore the financial needs of the program may be significantly different. And as you re-budget your project, think in terms of items you need that would yield economic benefit. Cited as an exceptional use of funds was the possibility of a postdoc staying in a lab instead of trying to find a job in a slow job market. A one-time equipment purchase that might help other local economies was also mentioned as compelling.

• Be ready to spend – If you do receive stimulus funds, NIH would like them spent as quickly as possible. They are under the requirement of awarding them by September 2010, and overseeing their expenditure. In the phone conference, Dr. Kington specifically said they would also like to see a bulk of the funds spent by 2010. NSF has been less aggressive so far when talking about their spending expectations.

• Be ready to report – Stimulus funds are different than dollars from a federal agency’s yearly appropriation. These funds will carry special reporting requirements about job creation and expenditure rates. Read your award notices carefully and understand the role you play in getting information back to sponsors.

This is a unique opportunity, and we hope that many will have the chance to participate. If you have questions or would like to talk to someone about options, we advise you to be in touch with your department research administration staff or contact the Office of Research’s Grant Review & Analysis unit (hmills@umich.edu). We will do our best to connect you to needed resources in order to advance your science. Read more about the stimulus funds to NIH below in the “Update from Washington, DC” section.

Annual Outside Interest Disclosure Required Using M-Inform

Deadline: March 31, 2009

As in previous years, all Medical School faculty members (instructional, clinical and research tracks) are required to disclose their outside interests annually each March 1 and as needed, indicating any involvement with University related activities outside the scope of their primary responsibility as a University faculty member. New this year is the inclusion of all house officers in this reporting requirement.

To comply with this UMHS Conflict of Interest policy, certain executives and management staff must also disclose their outside interests for themselves and their family members.

Key Points Include:

1. Outside Interest Disclosure Form (M-Inform) must be completed between March 1 and March 31.
2. Disclosure forms will be reviewed between April 1 and April 30, with follow-up as needed.
3. Upon signing and submitting the form, MLearning will track your completion.
4. Disclosures and any additional information gathered shall be treated as sensitive data, and access to this information is granted only to those University or UMHS personnel requiring such information to perform their duties.
5. The UMHS Conflict of Interest and Outside Interest Disclosures website (http://www.med.umich.edu/u/coi) is available to provide additional information on this process.

Access to M-Inform is at (http://www.umms.med.umich.edu/minform/). This electronic format provides an easy mechanism for submitting disclosures and allows participants to copy activities disclosed in 2008 into their...
BAC Recombineering Core Update

Bacterial artificial chromosome (BAC) libraries with all the genes from human, mouse, and other species are commercially available. Modification of the large genomic inserts to reproduce disease-causing mutations or to mark cells expressing certain genes is done by recombineering. The Recombineering Core Facility was established in the Transgenic Core by a partnership with the Endowment for the Basic Science, the Diabetes Research and Training Center, the Cancer Center, the Gastrointestinal Peptide Center, the Life Sciences Institute and the Center for Organogenesis. The Recombineering Core has set up a wet lab for and is recombineering BACs for pilot projects. Several BACs have been successfully modified with lacZ and red fluorescent proteins. Plasmid vectors to introduce other genetic markers (green fluorescent protein and Cre recombinase) are under construction in the Core. DNA sequencing of modifications and BAC fingerprinting are used for quality control purposes. We will continuously refine our methodology as we work through pilot projects. After we recombine a few more BACs we will open the BAC Recombineering Core to the research community at large. If you are interested in BAC services, please contact Thom Saunders (tsaunders@umich.edu).

RESEARCH COMPLIANCE
TRAINING AND EDUCATION

Human Research

eResearch Regulatory Management System Upgrade

The eResearch Regulatory Management system was upgraded on Monday, March 2, 2009. The upgrade or enhanced system release 2.0 is in response to feedback received from investigators and study teams requesting a more streamlined application. The enhancements for this upgrade include:

- New look and feel for the system workspaces and forms.
- Improved help sections.
- New, shorter, customized application paths for Exempt and Not Regulated projects.
  - An Exempt research application path that is limited to information necessary to determine whether a project meets the exemption criteria.
  - A Not Regulated application path for projects that do not fall under HHS or FDA regulations. For projects that do not require IRB review, the Not Regulated path can be used to generate a self-determination letter for funding or publication purposes. For projects that require IRB review only for compliance with HIPAA, other regulations or institutional policies, the Not Regulated path is limited to questions relevant to those determinations.
- A NEW Edit Study Team Member Activity has been added which will allow study teams to edit “non-key personnel” to have access to approved studies without having to submit an amendment. Study team members with the role of Staff, Consultant, or Other are considered non-key personnel.
- Updated amendment approval process so that only changes requiring review by ancillary and non-IRB core committees will be routed to those committees.

Because of the streamlining project, many questions that were not required have been deleted from the application. For example, with the new Exempt customized application path, a total of 57 questions have been eliminated from that application process. Approximately five questions have been added due to regulatory changes and certification requirements for the Association for the Accreditation of Human Research Protection Programs (AAHRPP).

For more information and detail about this release, please refer to (http://www.umich.edu/~eresinfo/erm/release2_0.html). For more information on what types of human subjects research are considered Exempt or Not Regulated, please refer to (http://www.research.umich.edu/hrpp/OM/Part4.html). For questions or further assistance, contact the MAIS Help Desk (734-936-7000, option 6 or maishelpdesk@umich.edu) or a U-M IRB (http://www.research.umich.edu/hrpp/IRBs.html).

Animal Research

Safety Reminder for the Research Facilities

The University of Michigan maintains an exemplary animal care and use program. Our animal care and use program maintains full compliance with federal and state regulations and policies, as well as nationally accepted professional standards. Because we are indebted to animals for their valuable contributions to our research and instructional endeavors, and because animal well-being is critical to good science, the University ensures that animals are used in a responsible, respectful, and humane manner. However, there are individuals that disagree with the use of animals in research. Because of this, we should all be especially alert to maintaining security in and around our laboratories and animal facilities.

The Department of Public Safety (DPS) always recommends that the research community take the following precautions:

- Keep laboratories and offices locked.
- Monitor laboratories and offices for unauthorized persons.
- Wear identification badges at all times.
- Report suspicious persons, activity, or objects to DPS immediately (call 911).
- Report inquiries regarding building hours, locations of laboratories and offices, type of research being conducted, and location of animals to DPS (734-763-3434).

Inspections of Animal Facilities

Both the Public Health Service Policy (PHS Policy) and the Animal Welfare Regulations require semi-annual inspections of animal facilities. In March / April and September / October, the UCUCA inspects animal housing and use rooms, facilities, and laboratories using the “Guide for the Care
and Use of Laboratory Animals” as a basis for evaluation. In addition, the UCUCA compliance staff inspects laboratory spaces that conduct rodent survival surgeries semi-annually on behalf of the UCUCA. The results of these inspections are reviewed by the UCUCA at a monthly meeting and sent in a report to the Vice President for Research twice each year.

Animal Concern Hotline
The UCUCA maintains the Animal Concern Hotline, operated through the UCUCA Office, to provide a mechanism for UM staff members and members of the public to report any matter of concern about the humane care and use of laboratory animals at the University. Reports are investigated on behalf of the UCUCA by the UCUCA Office staff and, if necessary, by a ULAM veterinary faculty member. Immediate steps are taken to ensure that animal care and use are appropriate and that animal welfare is sustained. The UCUCA is apprised of these investigations and their outcomes at their monthly meetings and makes further recommendations, if warranted. Reports and sources of information are maintained in confidence within University guidelines. To report an animal concern, please call 734-763-8028 or go to (http://www.ucuca.umich.edu/hotline.htm).

Training
Animal care training is based on regulatory requirements (Public Health Service Policy and the Animal Welfare Act) and the commitment of the University of Michigan to ensure that animal research performed here is done in the most humane and effective manner. As the animal research program has grown over the years, it has become necessary to increase staff and develop new ways of providing support to animal users. In order to improve the utilization of training resources, increase the coordination of training activities and messages, and reduce redundancy in training, all of the training provided by ULAM and UCUCA is now combined into a centralized unit called the ULAM Training Core. By having trainers from each area work together we have improved the consistency and availability of courses offered to all of our customers.

The training core offices and wet laboratory moved from the North Ingalls Building (NIB) to the Life Sciences Building (LSI). Training is coordinated through the Training Core instead of the UCUCA office.

Training Core Offices
Location: 1016 LSI
Phone: 734-763-8039
Email: ulamtraining@umich.edu
Website: http://www.ulam.umich.edu/training.htm

FREQUENTLY ASKED QUESTIONS
The frequently asked questions (FAQs) highlighted here come from a list of FAQs for research maintained by the Office of Research. To see the complete list, visit (http://www.med.umich.edu/medschool/research/faq.htm).

Q) What do I do if I am offered (and accept) a significant financial interest outside of the University? How do I report a potential conflict of interest?
A) First, faculty and management staff will need to disclose their outside activity or interest in M-Inform (https://www.umms.med.umich.edu/minform/). M-Inform is the electronic disclosure system that will route your disclosure to your department chair or supervisor for approval. For visiting faculty, adjunct faculty, and all other staff, their potential conflicts of interest should be disclosed to their supervisor. For the disclosure form, visit (http://www.med.umich.edu/u/coi/Files/Blank_Disclosure_Form_-_M-Inform.pdf).

In addition, potential conflicts of interest need to be disclosed on Page 2 of the Proposal Approval Form or Material Transfer Form used by DRDA. eResearch also includes conflict of interest questions that will route potential conflicts to the appropriate committee for review.

Finally, if you are involved in a UMHS committee, you should advise your committee chair of any potential conflict related to your role on the committee.

FROM THE GRANTS OFFICE
Grants.gov and Adobe Forms
Many of you are aware that Grants.gov has moved electronic form submission from PureEdge to an Adobe platform. MSIS- and MCIT-supported computers in the Health System have had appropriate versions loaded. While many are glad to have moved away from PureEdge forms and the problems associated with them, Abode-based form sets are not free of glitches.

While improvements are being made, please read below highlights from Bob Beattie’s and Terri Maxwell’s (both of DRDA) warnings of glitches in the form sets and delivery system. We are sure that having investigators cognizant of the issues will help expedite problem solving.

• Be ready to submit early. Not just early in any deadline cycle, but early in the morning! Having a proposal finalized and loaded for DRDA to send in the morning hours will offer a better success of getting through Grants.gov and the NIH Commons. DRDA is experiencing noticeably slower (and impaired) submission delivery as the West Coast “wakes up” and is also submitting. Grants.gov has released a new server that has higher capacity, but there continues to be noticeable slow downs through the early-March deadlines.

• Uploading your application to the DRDA “drop box” does not count as meeting a sponsor deadline. Moreover, our trying to submit an application to Grants.gov does not meet the deadline either. Only a successful submission to Grants.gov will meet deadline requirements.
• **Upload only the final version to the DRDA server.**
  (This requirement will be obsolete as we start to use eRPM in April and can specify versions that are ready to go through the system.) You do not want to cause confusion between draft versions and finals to be sent. If you need someone to look at draft, attach it to an email!

• **Be sure you are using the correct version of Adobe.**
  As mentioned above, MSIS and MCIT have distributed (to imaged computers) versions of Adobe that are compatible. If you are using non-UM resources to prepare a proposal or a non-imaged campus computer, please make sure you are carrying 8.1.2, 8.1.3 or 9.0 version of Adobe Reader. There have been occasional issues reported with 8.1.2 and crashes that cause loss of data. Please make sure in 8.1.2 you are saving often – just in case.

Also, Bob Beattie has provided detailed information around the use of Key Personnel on Grants.gov forms:

A serious error has been discovered in the Adobe Forms concerning the Key Personnel section. If there is only one Key Person, other than the PI, once a “Role in Project” is selected the data cannot be removed. This means that the person cannot be removed and the application cannot be submitted due to missing data in the other fields. If you expect to have only one Key Person in an application, I suggest you do not select the role on project for that person until just before you send the forms to the DRDA Dropbox. You might otherwise consider having two versions of the application, a completed one, and one lacking this field. Use the full application for creating materials for the Administrative Shell, and if the one Key Person stays with the project, upload that version. If, however, that one Key Person drops out of the project, use the incomplete version and remove the other data for that person and upload this version. If you find yourself with one Key Person, feel free to call me for further information, if you need it.

The Medical School is very appreciative of the information passed along from campus as well as for the dedication of the DRDA staff dealing with Grants.gov and Adobe forms under fire of deadlines!

If you have questions about this article, please contact Heather Offhaus in the Medical School Grant Review & Analysis Office (734-763-4272).

**UPDATE FROM WASHINGTON, DC**

**NIH Receives $10.4 Billion in Economic Stimulus Funds**

On February 17, 2009, President Barack Obama signed the American Recovery and Reinvestment Act (ARRA) into law. Of the $789 billion total, $10.4 billion will be allocate to the National Institutes of Health (NIH) to support research, construction and renovation activities. Below is a summary of how the NIH plans to spend the ARRA money. It is important to note that all information related to ARRA implementation can be found at a new federal website named “recovery.gov.”

**Research**

• $8.2 billion for biomedical research.
• $7.4 billion for the Institutes and Centers and the Common Fund. These funds will be allocated in proportion to the FY09 appropriations made to the Institutes, Centers, and Common Fund.
• $800 million for the Office of the Director for short-term grants. These grants will focus on specific challenges, new research that expands the scope of ongoing projects and research on public and international health priorities.
• Research funding will be allocated in one of three ways:
  • Standard investigator grants judged to be “highly scientifically meritorious” in peer review last year but did not receive funding.
  • Supplements to existing grants (such additions will not be made by formula but will be based on scientific opportunity and public health needs).
  • Two-year Challenge Grants aimed at supporting cross-cutting research.
• All grants to be made assuming a two-year obligation and expense.
• The selections will be made on the basis of peer review, with emphasis on the short-term stimulative nature of the proposal.
• There will be no automatic funding of existing proposals or grants.
• Reporting requirements will be more extensive (e.g. number of jobs retained or created will be required).
• There will be no formulaic restoration of money to centers or grants that during negotiations received less than requested.
• Unlike the earlier House and Senate bills, the final bill does not highlight specific areas of research as priorities.

**Infrastructure**

• $1.3 billion for construction and renovation as well as shared instrumentation.
• $1 billion for competitive awards for construction and renovation of extramural research facilities. Priority will be given to proposals that demonstrate energy savings or beneficial environmental effects.
• $300 million for shared instrumentation.

**EDUCATIONAL OPPORTUNITIES**

**44th Graduate Summer Session in Epidemiology**

**Application Deadline: June 1, 2009**

Applications received by the deadline does not guarantee placement in a course. Enrollment is limited in a number of courses.)

The University of Michigan School of Public Health will offer one-week and three-week courses for all public health professionals and those interested in health research during their 44th Graduate Summer Session in Epidemiology to take place July 12-31, 2009. Topics include: Fundamentals of Biostatistics and Epidemiology, Intermediate Methods, Infectious Diseases, Applied Public Health Practice, Cancer Epidemiology, Clinical Trials, SAS, Logistic Model,
Biomedical News • March 2009

FUNDING/AWARD OPPORTUNITIES

Funding opportunities listed below are for external limited submissions and/or opportunities within the University of Michigan only. To search for other funding and recognition opportunities, visit (http://www.med.umich.edu/medschool/research/support/funding.htm). This webpage contains a link to M-Quest (a database of opportunities for grants, honors, prizes and fellowships created and maintained by the Office of Research) as well as information on email alert groups.

Internal Submissions

Michigan Institute for Clinical and Health Research (MICHR) CTSA K Scholars Program

Deadline: Extended to March 16, 2009

The Michigan Institute for Clinical and Health Research is pleased to announce an extension in the application period and a revision to the funding support mechanism for the CTSA K Scholars-Mentored Clinical Scientists Development Program. The revision provides for full funding of two awarded scholars and partial-funding of four additional scholars. The top two applicants will be awarded full financial and training support for salary, research expenses and tuition fees. Four additional scholars will receive a total of $55,000 of support per year for research expenses and tuition/workshop fees. Partially funded scholars will be responsible for obtaining salary support from their clinical departments. The CTSA K Program is a two-year program offered to candidates from all healthcare-related schools and clinical departments who seek training as a clinical/translational research scientist. All applicants must obtain 75 percent protected time (50 percent for surgical sub-specialties) from their clinical departments. Applications can be obtained by visiting (http://www.michr.umich.edu/KL2/).

Eligible investigators include:

- New investigators without current or past NIH research project support (R01, P01, or current R55) as a principal investigator to engage in innovative research. New investigators should be clearly independent and have a faculty appointment higher than that of Lecturer/Postdoctoral fellow.
- Established investigators with no previous work in research related to the focus of the RDCC who are willing to test the applicability of their expertise on a problem related to rheumatic diseases.
- Established investigators in the RDCC with a proposal for testing the feasibility of a new or innovative hypothesis that is related to the research focus of the RDCC, but represents a clear and distinct departure from the investigator’s ongoing research interest.

For more information, visit (http://sitemaker.umich.edu/rheumaticdiseasescorecenter/call_for_applications).

Michigan George M. O’Brien Renal Core Center Pilot/Feasibility Study Grant Program

Deadline: March 17, 2009 (Letter of Intent)

New and innovative approaches—clinical, translational and basic—are sought to study kidney disease. The Michigan George M. O’Brien Renal Core Center P/FS Grant Program provides funds to promote research initiatives by new and established University of Michigan faculty in the area of kidney disease. Particularly encouraged are applications from junior investigators and investigators external to the renal community who have training and expertise that can be applied in innovative fashion to the study of kidney disease. The goal of the program is to enable investigators to generate preliminary data sufficient to successfully apply for major research funding from national funding agencies.

The grants are up to $50,000 per year for up to two years. Eligible investigators include: (1) new investigators without current or past NIH support as a principal investigator, and whose current or previous support from other sources has been modest; (2) established investigators with limited previous kidney research experience who wish to apply their expertise to a problem in this area; and (3) established renal investigators who propose testing innovative ideas that represent a clear departure from their ongoing research directions. Visit (http://www.med.umich.edu/medschool/research/support/kidneyresearch.pdf) for more information.

Rheumatic Diseases Core Center Pilot and Feasibility Research Funding

Deadline: April 10, 2009

Faculty members of the University of Michigan are invited to submit proposals for pilot and feasibility research projects to be funded through the U-M Rheumatic Diseases Core Center (RDCC) grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The Rheumatic Diseases Core Center is a multidisciplinary National Institutes of Health funded center that supports research in the etiology and pathogenesis of rheumatic diseases.

For application and information, visit (http://www.sph.umich.edu/epid/GSS). For questions, contact Jody Gray at 734-764-5454 or (umichgss@umich.edu).

Distance Learning Courses:

- Fundamentals of Biostatistics
- Fundamentals of Epidemiology
- CME credit available

For application and information, visit (http://www.sph.umich.edu/epid/GSS). For questions, contact Jody Gray at 734-764-5454 or (umichgss@umich.edu).
of this RFA is to facilitate and support clinical translational research in its many forms and to encourage interdisciplinary collaboration.

Proposals are sought from basic, clinical and social scientists from bench to bedside, bedside to practice, practice to interventions, and dissemination to policy research to promote development of transformative solutions for improving patient outcomes. All faculty and post-doctoral trainees at UM are eligible to apply as Principal Investigators. Basic scientists are encouraged to submit their application with a clinical scientist collaborator.

Special Focus RFAs supporting the CTSA vision requested for this round include “Community-University Research Partnerships,” “Health Disparities Research” and “Research Ethics.” New this round, the “Research Into Practice” focus RFA seeks investigators to develop and lead clinical translational research studies in partnership with GRIN, the Great Lakes Research Into Practice Network. The MICHR Research Into Practice program supports one-year pilot and/or feasibility research studies of innovative interventions and/or techniques designed to improve/benefit the health of the community.

For more details regarding Pilot Grant Program, descriptions of grant mechanisms and application instructions, visit (http://www.michr.umich.edu/programs/pilot-grant.html). For questions, contact Carol Van Huysen, MICHR Pilot Program Manager (734-998-6885 or cvanh@umich.edu).

**Michigan Gastrointestinal Peptide Research Center Pilot Feasibility Projects**

**Deadline: April 17, 2009**

The Michigan Gastrointestinal Peptide Research Center invites applications for Pilot Feasibility Projects in any of the following areas:

- Regulatory peptide biology
- Gastrointestinal Peptidergic Function
- Other areas of gastrointestinal function or pathology
- Microarray Gene Chip Technology and Proteomics applications designed to elucidate peptide involvement in GI function and pathology.

First priority will be given to young investigators at the University of Michigan embarking on a research career, with the hope that the Pilot Feasibility Project will lead to the successful funding of an RO1 type application. At least three years of postdoctoral training is required prior to the start of the award. Postdocs meeting this requirement, instructors/lecturers and young faculty through Assistant Professors are welcome. More senior investigators will be considered only if the project represents a new direction in their research, and will be given lower priority.

Grants will be awarded for $10,000 to $25,000; the maximum request is for $25,000/year. A maximum of two years of funding will be provided. For complete information, visit (http://www.med.umich.edu/mgpc/pilot).

**UM Postdoctoral Translational Scholars Program**

**Deadline: April 17, 2009**

The Postdoctoral Translational Scholars Program is a multidisciplinary career development program supported by the Michigan Institute for Clinical and Health Research (MICHR) that is designed to prepare individuals with a Ph.D. in a biomedical science or social science discipline for independent careers in translational research. The program is open to talented individuals who have completed a Ph.D. program in any of the basic sciences or related areas (biomedical, health, or social sciences) and aspire to develop a career in clinical translational research. Candidates must be a U.S citizen or permanent resident.

The program will provide trainees with a $100,000 career development award that can be utilized over two to three years. Award funding can be used to support the individual’s stipend, course work, and/or research activities. Postdoctoral Translational Scholars will be expected to commit 50 to 75 percent of full time effort to the program. For more information and an application, visit (http://www.michr.umich.edu/pltsp).

**UM Henry Russel Lectureship**

(http://www.rackham.umich.edu/faculty_staff/)

**UMMS AWARDED GRANTS**

**External Awarded Grants**

Currently, due to limitations on data collection, we are unable to identify projects awarded with multiple PIs. As the eRPM system is used for proposals in 2009, we will be able to publish those awards accurately. We apologize for any misleading project information this causes.

**Cell & Developmental Biology**

PI: Giger, Roman
Title: DEVELOPMENT OF MONOCLONAL ANTIBODIES SPECIFIC FOR DEGENERATING CNS MYELIN
Sponsor: Adelson Medical Research Foundation
Project Dates and Amount of Award: 07/01/08-06/30/09; $24,158

PI: Giger, Roman
Title: MECHANISMS OF NEURONAL GROWTH INHIBITION IN VITRO AND IN VIVO
Sponsor: Adelson Medical Research Foundation
Project Dates and Amount of Award: 07/01/08-06/30/09; $21,719

**Comprehensive Cancer Center**

PI: Talpaz, Moshe
Title: TAK-901 IN SUBJECTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES (UMCC 2008.046 A PHASE 1 DOSE ESCALATION STUDY OF)
Sponsor: Millennium Pharm, Inc.
Project Dates and Amount of Award: 11/14/08-05/13/10; $693,914

**Dermatology**

PI: Dlugosz, Andrzej
Title: THE HEDGEHOG PATHWAY IN CANCER DEVELOPMENT AND MAINTENANCE
Sponsor: Helen L. Kay Charitable Foundation
Project Dates and Amount of Award: 01/01/09-12/31/10; $57,816
**Family Medicine**

**Project Dates and Amount of Award:** 01/01/09-01/31/11; $120,000

**Internal Medicine**

**Project Dates and Amount of Award:** 01/01-12/31/10; $200,000

**Molecular & Behavioral Neuroscience Institute**

**Project Dates and Amount of Award:** 01/01/09-12/31/10; $90,000

**Molecular & Integrative Physiology**

**Project Dates and Amount of Award:** 01/01/09-12/31/09; $150,000

**Neurology**

**Project Dates and Amount of Award:** 01/01/09-12/31/09; $15,000

**Neurosurgery**

**Project Dates and Amount of Award:** 01/01/09-12/31/09; $92,281

**Obstetrics & Gynecology**

**Project Dates and Amount of Award:** 01/01/09-12/31/10; $10,000

**Ophthalmology & Visual Sciences**

**Project Dates and Amount of Award:** 01/01/09-12/31/10; $75,000
Neurology

Neurosurgery

Obstetrics & Gynecology

Ophthalmology & Visual Sciences

Orthopaedic Surgery

Otolaryngology

Pediatrics & Communicable Diseases

Pediatrics

Biomedical News • March 2009


Pasca SP, Nesse RM. Vomiting is not an adaption for glaucoma (and Darwinian medicine is difficult). Medical Hypotheses. 2008; 71(3): 472-3.


Surgery

General Surgery:

Dehass AM, Wolters NM, Keller ET, Ignatouski KM. EGFR Ligand Switch in Late Stage Prostate Cancer Contributes to Changes in Cell Signaling and Bone Remodeling. Prostate. 2009 Jan 13 (Epub ahead of print).


Pediatric Surgery:

Ehrlich PF, Maio K, Drongowski R, Wagaman M, Cunningham R, Walton M. Alcohol Interventions for Trauma Patients are not Just for Adults. Justification for Brief Interventions for the Injured Adolescent at a Pediatric Trauma Center. Journal of Trauma. 2009 (Accepted).


Thoracic Surgery


Vascular Surgery:


Unit for Laboratory Animal Medicine


Urology


Margulis V, Shariat SF, Matin SF, Kamat AM, Zigueuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG; the Upper Tract Urothelial Carcinoma Collaboration. The Upper Tract Urothelial Carcinoma Collaboration members: Charles C. Guo, University of Texas M.D. Anderson Cancer Center, USA; Wareef Kabbani, Stephen Lucas, Arthur I. Sagalowsky, The University of Texas Southwestern Medical Center, USA; Cord Langner, University of Graz, Austria; Karim Bensalah, Jacques Jadot, CHU Pontchaillou, Rennes, France; Shuji Mikami,takeo Kosaka, Masaru Isida, Keio University School of Medicine, Japan; Mesut Remzi, Andrea Haitel, Matthias Waldert, University of Vienna, Austria; Pierre I. Karakiewicz, Nazareno Suardi, University of Montreal; Marco Roscigno, Roberto Bertini, Francesca Montorsi, Vitale University, Italy; Christian Bolenz, Philipp Stroebel, Maurice Stephan Michel, Universitätsklinikum Mannheim; Casey N. Ng, Douglas S, Scherr, Yingbei Chen, Cornell University, USA; Mario A. Fernández, Clinica Alemana de Santiago, Chile; Jeffrey Wheat, J. Stuart Wolf, Jr., University of Michigan, USA; Theresa M. Koppie, Christopher P. Evans, Eric C. Nelson, University of California Davis Medical Center, USA; Wassim Kassouf, McGill University, Canada. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009 Jan 20 (Epub ahead of print).


